Boston Scientific completes trial enrolment for Adapt stent

Boston Scientific has completed patient enrolment for a new post-market clinical follow-up study designed to evaluate its Adapt Monorail carotid stent system.

The ASTI trial, which commenced in 2010, is assessing the stent in combination with the FilterWire EZ embolic protection system for treating carotid artery disease in patients at high risk for carotid surgery.

It has now reached its recruitment target of 100 patients at 11 sites across Europe and will be examining the rate of major adverse events, as well as the occurrence of late ipsilateral stroke, target lesion revascularisation and in-stent restenosis.

The Adapt carotid stent has been available in Europe since 2010 and has received CE Mark approval.

Jeff Mirviss, president of Boston Scientific's peripheral interventions division, said: "Physician experience with the Adapt stent has been excellent since its introduction in Europe last year."

Last week, the firm launched the Interlock – 35 Fibered IDC Occlusion System in the EU and US after being granted regulatory clearance.